Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy.Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease.The journal welcomes:Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicineDrug evaluations reviewing the clinical data on a particular biological agentOriginal research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;Article Highlights – an executive summary of the author’s most critical points.
生物疗法专家意见（1471-2598; 1744-7682）是一个MEDLINE索引，国际期刊发表生物治疗各个方面的同行评审研究。每篇文章的结构都包含作者自己的专家意见，这些意见涉及主题对研究和临床实践的影响以及未来发展的范围。受众包括医疗保健和生物制药行业的科学家和管理人员，以及其他密切参与开发和生物疗法在人类疾病治疗中的应用。该杂志欢迎：综述，涵盖治疗性抗体和疫苗，肽和蛋白质，基因疗法和基因转移技术，基于细胞的疗法和再生医学药物评估回顾特定生物制剂的临床数据原创研究论文，报告生物制剂的临床研究结果和基于生物疗法的研究，与临床实践有很强的联系。每一篇综述的全面报道都由独特的专家收藏格式补充，包括以下部分：专家意见-对文章中数据的个人观点，对未来可能重要的发展的讨论，以及随着进一步研究产生更详细的结果而可能变得令人兴奋的研究途径;文章亮点-作者最关键点的执行摘要。
Complement inhibition as a therapeutic strategy in retinal disorders
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1575358
A vaccine against Alzheimer`s disease: anything left but faith?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1554646
Stem cell therapies for wound healing
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1596257
B cell depletion in the treatment of multiple sclerosis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1568407
Inflammatory cytokines: from discoveries to therapies in IBD
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1652267
Etanercept biosimilar SB-4
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1566456
Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1554053
Tocilizumab for the treatment of adult-onset Still’s disease
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1590334
Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1685976
An update on therapies for the treatment of diabetes-induced osteoporosis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1618266
Current and emerging biologics for the treatment of hereditary angioedema
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1595581
Biosimilars for the treatment of psoriasis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1636963
Immunotherapeutic approaches in nasopharyngeal carcinoma
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1650910
An update on immunotherapy options for urothelial cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1667975
Facing the future: challenges and opportunities in adoptive T cell therapy in cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1608179
IL-17 inhibition in axial spondyloarthritis: current and future perspectives
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1605352
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1571580
Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1651288
Disease modeling of cardiac arrhythmias using human induced pluripotent stem cells
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1575359
Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1707800
NK cell-based therapeutics for lung cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1688298
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1561852
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1644316
iNK-CD64/16A cells: a promising approach for ADCC?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1667974
Moxetumomab pasudotox for the treatment of hairy cell leukemia
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1614558
Endogenous lung stem cells for lung regeneration
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1596256
Pembrolizumab for the treatment of diffuse large B-cell lymphoma
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1659777
Immune checkpoint inhibition for the treatment of renal cell carcinoma
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1677601
Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1610380
Defining the immunogram of breast cancer: a focus on clinical trials
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1598372
RPGR gene therapy presents challenges in cloning the coding sequence
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1680635
Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1582635
Mesenchymal stromal cells for ocular surface repair
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1607836
Towards personalized treatment in atopic dermatitis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1583204
Curcumin: footprints on cardiac tissue engineering
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1650912
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1623875
Histological healing: should it be considered as a new outcome for ulcerative colitis?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1701652
Choosing the most appropriate biologic therapy for Crohn’s disease according to concomitant extra-intestinal manifestations, comorbidities, or physiologic conditions
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1689953
Candidate vaccines for human Rift Valley fever
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1662784
Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1656715
Nivolumab for the treatment of unresectable pleural mesothelioma
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1703945
The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1566455
Biological therapy of autoimmune blistering diseases
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1559291
An overview of tolerogenic immunotherapies based on plant-made antigens
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1597048
Clinical development of CT-P6 in HER2 positive breast cancer
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1665019
Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1702020
Is there room for immunomodulators in ulcerative colitis?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1708896
Special considerations for biologic medications in pediatric ulcerative colitis
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2020.1685492
Bioengineering and regeneration of gastrointestinal tissue: where are we now and what comes next?
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1595579
Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation
来源期刊：Expert Opinion on Biological TherapyDOI：10.1080/14712598.2019.1673725
